Actively Recruiting
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
Led by University of Alabama at Birmingham · Updated on 2025-07-14
10
Participants Needed
1
Research Sites
338 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.
CONDITIONS
Official Title
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 40 and 85 years old
- Diagnosis of idiopathic pulmonary fibrosis that meets ATS/ERS 2018 consensus criteria within the last 5 years
- Ability and willingness to provide informed consent and follow study procedures
- Forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) ratio greater than 0.70
- High or mixed affinity binder for TSPO ligands based on genotyping for SNP rs6971
You will not qualify if you...
- Acute exacerbation of idiopathic pulmonary fibrosis within the last 30 days
- Diagnosis of diabetes mellitus (Type 1 or Type 2)
- Current infection based on clinical or microbial assessments
- Treatment within the past month with more than 20 mg prednisone (or equivalent) for over 14 days or any cellular immunosuppressant in the last month
- Prior radiation therapy to the chest area
- Women who are pregnant or breastfeeding
- Severe cardiovascular disease within the past 12 weeks, including heart attack, unstable angina, coronary revascularization, or stroke
- Known liver disease
- Active cancer except for basal cell carcinoma of the skin
- Low affinity binder for TSPO ligands based on SNP rs6971 genotyping
- Active cigarette smoking or vaping
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35249
Actively Recruiting
Research Team
J
Jonathan McConathy, MD, PhD
CONTACT
A
April Riddle, BSRT
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here